True To Its Cancer Focus, Medarex Outlicenses C. Diff Therapy To Merck
This article was originally published in The Pink Sheet Daily
Executive Summary
Medarex and partner Massachusetts Biologic Laboratories will split equally $60 million upfront and potential milestones worth $165 million.